Blueprint Medicines Corporation

Total Valuation

Blueprint Medicines Corporation carries a market capitalization of 8.36B, placing it among publicly traded companies globally. Its enterprise value stands at 5.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Blueprint Medicines Corporation currently has 64.56M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 10.00, and the price-to-book ratio stands at -2.33.

Enterprise Valuation

Financial Position

Blueprint Medicines Corporation maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 136.41, indicating elevated leverage, while an interest coverage ratio of -2.21 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Blueprint Medicines Corporation has paid 1.84M in income taxes, reflecting an effective tax rate of 61.40.

Stock Price Statistics

Blueprint Medicines Corporation's stock has gained approximately 35.27691% over the past 52 weeks. The 50-day moving average sits at 116.52, while the 200-day moving average is 98.82.

Income Statement

Over the trailing twelve months, Blueprint Medicines Corporation generated 562.12M in revenue and converted that into -155.73M in net income, yielding earnings per share of -2.43. EBITDA reached -158.37M, while operating income came in at -174.31M.

Balance Sheet

Blueprint Medicines Corporation holds 576.24M in cash and equivalents against 466.70M in total debt, resulting in a net debt position of 265.50M. Total book value stands at -2.41B, with working capital of 451.49M providing operational flexibility.

Cash Flow

Blueprint Medicines Corporation produced -145.55M in operating cash flow over the past twelve months. After subtracting -5.36M in capital expenditures, free cash flow totaled -150.91M - equivalent to -2.38 per share.

Margins

Blueprint Medicines Corporation operates with a gross margin of 96.48, reflecting its pricing power and cost economics. The operating margin of -31.01 and net profit margin of -27.70 provide insight into operational efficiency.

Dividends & Yields

Scores

Blueprint Medicines Corporation posts an Altman Z-Score of 1.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.